Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Arachidonic Acid Pathway

  • Henk J. van Kranen
  • Christine L. E. Siezen
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_380-3



The arachidonic acid pathway describes the biosynthesis of eicosanoids from arachidonic acid (AA) including its formation from omega-6 polyunsaturated fatty acids (PUFAs) and the synthesis of eicosanoids from eicosapentaenoic acid (EPA) including its formation from omega-3 PUFAs. Eicosanoids are short-lived biologically potent, autocrine or paracrine acting, lipid signaling molecules.


The AA pathway is involved in many physiological processes including inflammationand cancer. The pleiotropic effects of modulating this pathway are manifold and are depending on the levels of fatty acids from (dietary) substrates, which in turn modulate the level of eicosanoid precursors (AA and EPA) determining the amounts of eicosanoid lipid mediators actually produced. Initial and still ongoing research on the pharmacological inhibition of inflammatory reactions by nonsteroidal antiinflammatory drugs...


Arachidonic Acid Familial Adenomatous Polyposis Free Arachidonic Acid Sulindac Sulfide Arachidonic Acid Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Buchanan FG, Dubois RN (2006) Connecting COX-2 and Wnt in cancer. Cancer Cell 9(1):6–8CrossRefPubMedGoogle Scholar
  2. Furstenberger G, Krieg P, Muller-Decker K et al (2006) What are cyclooxygenases and lipoxygenases doing in the driver’s seat of carcinogenesis? Int J Cancer 119(10):2247–2254CrossRefPubMedGoogle Scholar
  3. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79(6):935–945PubMedGoogle Scholar
  4. Ulrich CM, Bigler J, Potter JD (2006) Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6(2):130–140CrossRefPubMedGoogle Scholar
  5. Weylandt KH, Kang JX (2005) Rethinking lipid mediators. Lancet 366(9486):618–620CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Henk J. van Kranen
    • 1
  • Christine L. E. Siezen
    • 1
  1. 1.National Institute of Public Health and EnvironmentBilthovenThe Netherlands